Q. Lecocq

发表

Single‐domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages

Y. De Vlaeminck, Q. Lecocq, Philippe Giron, 2019, Journal of controlled release : official journal of the Controlled Release Society.

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches

Z. Berneman, H. Sugiyama, Q. Lecocq, 2018, Oncotarget.

Theranostics in immuno-oncology using nanobody derivatives

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2019, Theranostics.

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm

N. Devoogdt, Q. Lecocq, K. Breckpot, 2020, International journal of molecular sciences.

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

C. Vanhove, N. Devoogdt, Q. Lecocq, 2020, Biomolecules.

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

N. Devoogdt, Q. Lecocq, K. Breckpot, 2018, Theranostics.

Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production

N. Devoogdt, Q. Lecocq, K. Thielemans, 2019, Vaccines.

Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2021, The Journal of Nuclear Medicine.

Nanobody nuclear imaging allows noninvasive quantification of LAG- 3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade

N. Devoogdt, Q. Lecocq, K. Thielemans, 2021 .

Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

A. Windhorst, N. Devoogdt, Q. Lecocq, 2020, Cancers.

Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry

N. Devoogdt, Q. Lecocq, K. Breckpot, 2021, Pharmaceuticals.

Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development

M. Mazzone, Y. De Vlaeminck, Q. Lecocq, 2020, Cancers.

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

N. Devoogdt, Q. Lecocq, S. Schoonooghe, 2019, Cancers.

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy

J. Timmermans, Y. De Vlaeminck, Q. Lecocq, 2022, Frontiers in Immunology.

Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2021, EJNMMI Research.

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2019, Biomolecules.

Vrije Universiteit Brussel Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use Lecocq,

N. Devoogdt, Q. Lecocq, Sam Massa, 2019 .

Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade

M. Verdonck, A. Van Parys, N. Devoogdt, 2021, Molecular therapy. Methods & clinical development.

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

F. Prósper, X. Agirre, V. Basso, 2022, Frontiers in Immunology.

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

Marleen Keyaerts, Nick Devoogdt, David Escors, 2017, Oncotarget.

Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

N. Devoogdt, Q. Lecocq, C. Goyvaerts, 2023, The Journal of Nuclear Medicine.

Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2022, Molecular cancer therapeutics.

The therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of ovarian cancer.

B. Miller, Q. Lecocq, V. Caveliers, 2020, Molecular pharmaceutics.

Nanobody nuclear imaging allows noninvasive quantification of LAG- 3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade

N. Devoogdt, Q. Lecocq, K. Thielemans, 2021 .

Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model

N. Devoogdt, Q. Lecocq, C. Goyvaerts, 2022 .

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

N. Devoogdt, Y. De Vlaeminck, Q. Lecocq, 2024, Frontiers in immunology.